Awareness of and Identifying Iron Overload in Transfusion-Dependent Patients Can Be Improved: A Retrospective Review At a Single Tertiary Care Centre

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 5283-5283
Author(s):  
Nicole Hugel ◽  
Cyrus C. Hsia

Abstract Abstract 5283 Awareness of and Identifying Iron Overload in Transfusion-dependent Patients can be improved: A Retrospective Review at a Single Tertiary Care Centre Nicole Hugel, HBSc1 and Cyrus C. Hsia, HBSc, MD, FRCPC2. 1Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada, 2Schulich School of Medicine and Dentistry, University of Western Ontario, Division of Hematology, Department of Medicine, London Health Sciences Centre, London, ON, Canada. Introduction: Several patient populations, including those with thalassemia, sickle cell disease, and bone marrow failure syndromes, often require red blood cell (RBC) transfusions and are at risk of iron overload. Chronic RBC transfusions lead to an increase in morbidity and mortality, particularly as a result of iron overload, proven in patients with thalassemia major and implicated in certain bone marrow failure syndromes such as myelodysplasia. Guidelines currently recommend iron chelation in these various clinical settings, yet the true incidence of iron overload and physician awareness patterns remain unknown. Iron overload is likely under recognized and under managed. We aim to determine the incidence of iron overload in transfusion-dependent patients in a general tertiary care centre and to determine if physicians are adequately screening for and considering treatment for iron overload. Methods: All adult patients at a single tertiary care centre, London Health Sciences Centre (LHSC), who received at least one RBC transfusion between January 1, 2006 and December 31, 2008, were captured through the local Blood Transfusion Laboratory (BTL) database. Patients who were deemed transfusion-dependent, defined as having received a minimum of 12 units of RBCs in any 12 month period with at least one RBC transfusion every 8 weeks, were identified for further analysis. This was based on the World Health Organization (WHO) criteria for RBC transfusion dependency in patients with myelodysplastic syndrome (MDS), where RBC transfusion dependency was defined as having at least one RBC transfusion every 8 weeks over a period of 4 months. Full chart reviews for these patients from the beginning of the study period to up to 12 months after the last transfusion in the LHSC BTL database during the study period were performed. For these transfusion-dependent patients, the number who had ferritin levels checked was determined. Those who had a ferritin level >1000μg/L were considered to have iron overload. Finally, of these patients who were transfusion-dependent with iron overload, full chart reviews during the study period were undertaken to determine if treating physicians considered monitoring for and treating the iron overload. Results: The LHSC BTL database included a total of 67449 RBC transfusions administered to 12486 unique patients during the study period. 1200 patients (6.6%) received at least 12 units of RBCs during the study period and were evaluated further. 48 adult patients (0.4%) satisfied the criteria for RBC transfusion dependence. Of the 48 transfusion-dependent patients, 40 (83.3%) had a ferritin value measured during and/or up to 12 months following the end of the study period. 30 (75.0%) transfusion-dependent patients with a ferritin measurement were deemed to have iron overload, consisting of patients with MDS (n=13), myelofibrosis (n=4), beta thalassemia (n=3), red cell aplasia (n=3), aplastic anemia (n=1), and other diagnoses (n=6). In this smaller cohort of 30 patients, 24 patients (80.0%) had physicians that referred to the possibility of iron overload in the clinical notes and only 16 patients (53.3%) were treated with iron chelation at some point during the study period. Conclusions: In a general tertiary care centre the percentage of transfusion-dependent patients is low compared to the total number of patients who are transfused. The percentage of transfusion-dependent patients who treating physicians monitored for or identified iron overload and subsequently managed were slightly higher than previous published rates. However, awareness of and identifying iron overload in transfusion-dependent patients at a general tertiary care centre can be improved. Disclosures: Hugel: Novartis: Unspecified Educational Fund.

2014 ◽  
Vol 61 (12) ◽  
pp. 2319-2320 ◽  
Author(s):  
Sameer Sait ◽  
Nibal Zaghloul ◽  
Ashish Patel ◽  
Tishi Shah ◽  
Ionela Iacobas ◽  
...  

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4013-4013 ◽  
Author(s):  
Rodolfo Cancado ◽  
Ivan Angulo ◽  
Zaida Plumacher ◽  
Mariela Moreno ◽  
Adriana Linares ◽  
...  

Abstract In Latin America (LA), miscegenation of populations of Mediterranean and African ancestry has occurred for several centuries, thus facilitating the spread of hemoglobin variants. The prevalence of thalassemias, sickle-cell disease (SCD) and other hemoglobinopathies, as well as of myelodysplastic syndromes (MDS) and other diseases associated with TH is largely unknown in LA. As a retrospective registry of pts with TH in LA, the RELATH Study provides a unique opportunity to gain insight about the prevalence of TH and the patterns of care for these pts in LA. Participating countries include Brazil, Colombia, Mexico, Peru, and Venezuela. Target accrual is approximately 1,000 patients. Cases are accrued by large-volume, tertiary-care hematology centers located in large cities through a CRF designed for the study. Treatment and pt evaluation are not influenced by the study. Eligible pts have age >2 yr, consultation in the participating institutions at least once since 01/04, any disorder requiring chronic red-blood-cell (RBC) transfusion, receipt of >9 RBC units, at least one value of serum ferritin >1000 mcg/L, and/or a liver iron content (LIC) >2 mg/g dry weight (pts. with leukemia are excluded). Between Jan/06 and May/07, 239 pts have been accrued, 236 of which are evaluable. The mean age was 29.2 +/− 20.4 (range, 2 to 92), and 53.8% of pts were female. Ethnic distribution was Hispanic (41.0%), African (34.6%), and Caucasian ancestry (24.4%). The most frequent diagnoses were SCD (43.6%), beta-thalassemia major (17.4%), aplastic anemia (13.6%), and MDS (7.2%, 53.3% of which had refractory anemia). RBC transfusion was > 9 in 100% and >19 in 89.8% of pts, and mean ferritin was 2564 +/− 1834 mcg/L. LIC determination was not available or not done in 90.6% of cases. The level of hemoglobin at which transfusion was indicated was 7 to 10 g/dL in 60.7%, and 6 g/dL or less in 38.1% (N/A in 1.3%). The mean number of transfusions received was 12.2 +/− 8.8/yr (range, 1 to 80). Iron overload was assessed using ferritin (93.2%), and TH related complications were evaluated with echocardiogram (42.8%), and liver US (27.5%). TH-related complications were reported in 82.2% of cases (66.5% of pts had hepatic complications, 32.6% endocrine, 16.1% cardiac). Iron-chelation therapy was given to 39.8% of pts, more frequently on the basis of ferritin (27.5%), number of transfusions (18.2%), and complication from iron overload (5.5%). Deferoxamine (93.6%) and deferasirox (6.4%) were the most frequent chelators. In most cases, treatment was still ongoing, but reasons for discontinuation were pt refusal (4.7%), drug no longer available (4.2%), and poor compliance (3.8%). In conclusion, this preliminary report from the ongoing RELATH study shows that a registry is feasible and may provide valuable information regarding TH in various countries of LA. In addition, the study suggests so far that most LA patients undergoing chronic transfusion develop TH, whose complications could be prevented by more effective use of iron chelation, which was relatively low in this sample.


2019 ◽  
Vol 6 (5) ◽  
pp. 2007
Author(s):  
Suman Chirla ◽  
Lalita Wadhwa ◽  
Puneet Wadhwa

Background: Thalassemic patients require regular blood transfusions to maintain haemoglobin level around between 10gm/dl-15gm/dl, which would result in transfusional iron overload. The treatment of iron overload is carried out by using parenteral desferrioxamine (DFX) therapy or recently introduced oral Deferiprone (DFP,L1,Ferriprox,KELFER,CP20) an oral iron chelator, Oral deferiprone, DFP (3-hydroxy-1,2-dimethylpyridin-4-one) is a synthetic analogue of mimosine, an iron chelator isolated from the legume Mimosa paduca. Our study was undertaken to asses ferritin concentration in transfusion dependent thalassemic children on Deferiprone, attending thalassemia clinic in Anil Neerukonda hospital, Sanghivalasa, Visakhapatnam.Methods: The present study was a hospital based prospective study, 50 transfusion dependent thalassemic children on Deferiprone, attending thalassemia clinic in Anil Neerukonda hospital, Sanghivalasa, Visakhapatnam attached to NRI Medical College, Visakhapatnam were enrolled during the study period October 2017 and September 2018.Results: In our study authors found an increase in Serum ferritin concentration from 3067.99±1520.13 to 4281.10 ±1760.42 ng/ml at the end of 12 months, which was quite significant.Conclusion: Authors concluded that oral Deferiprone is not an effective iron chelation agent and is associated with complications like GI symptoms, joint pains in significant number of children. So, search for an alternative iron chelator or combined chelation therapies which are safe and cost effective should be continued.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 5432-5432
Author(s):  
Drorit Grizim Merkel ◽  
Abraham Avigdor ◽  
Arnon Nagler ◽  
Ohad Benjamini ◽  
Yaron Davidovitz ◽  
...  

Introduction: Transfusion dependency in Myelodysplastic syndrome (MDS) patients is associated with shortened over-all survival and leukemia-free survival; however, it is not clear whether this detrimental effect is mediated by transfusional iron overload itself or whether the need for RBC transfusion is a surrogate marker of disease severity. Additionally, despite the negative effects of anemia and transfusion dependence on disease outcomes and patient quality of life, the clinical impact of iron overload in MDS remains controversial. Overall, the most common non-leukemic cause of death in MDS is heart failure. Recent T2* cardiac MRI (CMR) studies have shown that cardiac iron accumulation in MDS patients is variable and infrequent. T2* CMR is noninvasive, robust and the best available modality for assessing iron organ quantification. The current study assessed iron overload in transfusion dependent MDS patients using ferritin levels combined with myocardial and liver iron quantification using T2* CMR. The study monitored iron accumulation dynamics while on iron chelation therapy. Methods: We collected retrospectively clinical data in 18 RBC transfusion dependent MDS patients that had a CMR in our institution; some of the patients have serial scans. All scans were obtained using a 1.5 T scanner (Signa HDx ver 15 GE). Scans interpretation was performed using a dedicated workstation (Medis Medical imaging version 7.6, the Netherlands) for left ventricular ejection fraction measurement and T2* investigation as previously described. T2* values were recorded in milliseconds and converted to mg/gr dry tissue of myocardial liver and pancreatic tissue. Results: Ten of 18 patients were chelated. During the study period 4 patients have died from pneumonia, brain tumor, complications of Allo BMT and transformation to AML. Demographic data and prognostic score of MDS are shown in table 1. Before the first CMR, patients were treated with median of 48 PC (14-145) with median ferritin levels 1691.3ng/ml (269.4-3730ng/ml). In Table 2 we show iron accumulation in the first CMR. Iron accumulation in the heart was seen in 2 patients. The results are shown as severity of accumulation and not absolute numbers, as normal and abnormal range is different in the different organs. Seven patients had yearly serial CMR done, 6 of them were treated with iron chelation. We found iron accumulation in the heart in 4 of them. In table 3 we show example of a patient that was treated with chelation. Another patient, that had decrease ejection fraction with only moderate accumulation in the heart in CMR, improved her heart function with chelation. During the study period all patients continue to be transfusion dependent except 1 patient that became transfusion independent. She was transfused with 182 PC with maximal ferritin of 6926ng/ml. She was chelated with deferiprone and then with desferal. She is now transfusion independent for a year. Conclusion: Blood transfusion dependency in MDS patients, leads to high ferritin levels and evidences in CMR of iron accumulation in parenchymal orangs including the heart. During the study 4 patients had evidence of iron accumulation in the heart with 2 of them with severe accumulation that improved with iron chelation. Liver and pancreas accumulation was seen in 12 and 8 patients accordingly. Prospective studies documenting the correlation between chelation therapy and improvement in organ damage and survival are needed. Disclosures No relevant conflicts of interest to declare.


2017 ◽  
Vol 23 ◽  
pp. 289
Author(s):  
Vineet Surana ◽  
Rajesh Khadgawat ◽  
Nikhil Tandon ◽  
Chandrashekhar Bal ◽  
Kandasamy Devasenathipathy

JMS SKIMS ◽  
2020 ◽  
Vol 23 (1) ◽  
pp. 48-49
Author(s):  
Javaid Ahmad Bhat ◽  
Shariq Rashid Masoodi

Apropos to the article by Dr Bali, titled “Mupirocin resistance in clinical isolates of methicillin-sensitive and resistant Staphylococcus aureus in a tertiary care centre of North India” (1), the authors have raised important issue of emerging antimicrobial resistance (AMR). Antimicrobial resistance is an increasingly serious threat to global public health that requires action across all government sectors and society. As per WHO, AMR lurks the effective prevention and management of an ever-increasing spectrum of infections caused by bacteria, parasites, fungi and viruses. Novel resistance mechanisms are emerging and spreading globally, threatening the man’s ability to treat common infectious diseases.


Sign in / Sign up

Export Citation Format

Share Document